TABLE I.
Subject demographics.
| # | agea | % Fb | Therapyc | CD14d | CD4 | CD8A | CD19 | CD56 | FCGR3A | |
|---|---|---|---|---|---|---|---|---|---|---|
| MS-N | 8 | 34 ±3 | 83 | − | 1.26 | 1.04 | 0.88 | 1.16 | 0.89 | 1.13 |
| MS-E | 8 | 39 ±3 | 67 | + | 1.08 | 0.84 | 0.86 | 0.80 | 1.09 | 1.05 |
| HC | 8 | 38 ± 11 | 75 | − | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
a
Average age ± standard deviation, P > 0.05 compared to HC.
b
P > 0.05 compared to HC, all subjects were Caucasian.
c
Present therapy for multiple sclerosis
d
From RNA-seq data, ratios of expression of the different cell-type specific cell surface markers in each disease cohort compared to HC, P > 0.05 compared to HC; CD14, monocytes; CD4, helper T cells; CD8A, cytotoxic T cells; CD19, B cells; CD56, NK cells; FCGR3A (CD16) neutrophils.